Will Sepracor change its name to "Aptiom" on April 1? That's the speculation on CafePharma, where one anonymous commenter notes that the maker of the sleeping pill Lunesta, whose moth-filled ads have ...

Last year, Sepracor, the maker of sleeping pill Lunesta, announced it would reduce its sales and marketing expenses by $90-100 million in 2008, "including an anticipated reduction of approximately 300 ...

Marlborough-based drug maker Sepracor reported third quarter net income of $19.4 million, a sharp decrease from the $40 million the company reported for the same quarter last year. The company's third ...

Marlborough-based Sepracor Inc. has agreed to be acquired by Japanese drug firm Dainippon Sumitomo Pharma Co. for about $2.6 billion. Dainippon will purchase Sepracor in a cash tender offer of $23 per ...

Sepracor will eliminate 300 sales force positions as part of a cost cutting plan to reduce expenses by $90 million-$100 million for 2008. “We have examined our sales organization in depth,” Adrian ...

Sepracor will launch a $60 million dollar marketing and advertising campaign for its new sleeping pill Lunesta in the coming week. Ads for the drug will tout Lunesta’s advantages, Sepracor chief ...

During the last year, Sepracor (SEPR) has had a substantial correction in price, dropping over fifty percent. This significant decline has taken the market cap of the company to only $3.11B. Even with ...

LOS ANGELES (MarketWatch) -- Shares of Sepracor jumped more than 8 percent Thursday on reports that the drugmaker could be the target of a buyout and is evaluating strategic options. Sepracor SEPR ...

Overall planned operating expense reduction of approximately $210.0 million, of which approximately $20.0 million of cost savings was realized in the fourth quarter of 2008 and approximately $190.0 ...

Agreement provides Sepracor with a global license covering development of stable suspension formulations and nebule technology in ciclesonide inhalation solution for asthma and chronic obstructive ...

Sepracor (SEPR), maker of insomnia drug Lunesta, steamrolled through earnings yesterday. Sepracor posted 4Q earnings of $37.2 million, or 32 cents per share -- that reversed a loss of $33.7 million a ...